OR WAIT null SECS
The company will expand the site to include six new containment isolators and a product development manufacturing laboratory.
Vectura, an inhalation contract development manufacturing organization, announced on Dec. 12, 2020 that it is expanding its capabilities at its Chippenham, UK, facility to handle and develop highly potent active pharmaceutical ingredients (HPAPIs).
The expansion will include the installation of six containment isolators and the inclusion of a product development manufacturing laboratory that will house development manufacturing equipment for dispensing, blending, co-milling, jet-milling, spray-drying, and blister-filling, the company said in a press release. The new project will also increase the containment capabilities at the site, allowing Vectura scientists to handle APIs with an occupational exposure limit as low as 0.1 µg/m3.
“As a leading inhalation development company, we are committed to developing capabilities to meet our customers’ needs,” said Geraldine Venthoye, Vectura’s chief scientific officer and executive vice-president of Product Development, in the company press release. “Many inhaled drugs targeting, for example, asthma and COPD [chronic obstructive pulmonary disease], rely on high potency because of the small doses delivered, so this investment is crucial to ensure we have the physical capabilities to go alongside our scientists’ expertise to develop medicines and treatments in the future.”